HFA 134a Propellant: A Guide to Uses and Future
HFA 134a propellant (1,1,1,2-tetrafluoroethane of pharmaceutical grade), as a leading non-polluting care industry propellant, is one of the most mature short chain fluorocarbon products. HFA 134a propellant has found its place in the metered-dose inhalers (pMDIs) due to good performance and lower toxicity and serves as a pharmaceutical solvent and excipient in a variety of applications.
This article addresses for the first time, the definition, history, development, distinctions over the industrial-grade R134a, benefits and limitations as pharmaceutical propellant, and the key application cases of HFA 134a propellant. In enhances furthermore, it suggests future upgrade directions in light of regulatory trends and sustainable development requirements.
Contents
What is HFA 134a?
HFA 134a (Hydrofluoroalkane 134a, Chemical: 1,1, 1,2- Tetrafluoroethanc Common: A-S by DuPont.) a color less,odorless, non-flammable, low-boiling-point hydrocarbon gas. Following additional purification, including removal of essentially all residual chlorofluorocarbon 12 (CFC-12) and limiting also total other impurities to low parts per billion concentrations, HFA 134a propellant is used as an increasingly acceptable propellant for pharmaceutical metered dose inhalers such as MDI’s and pMDIs.
The characteristics of HFA 134a propellant:
Appearance: Boiling point is about -26.3 ℃, with moderate vapor pressure, and it could be liquefied easily for the storage;
Chemically Inert: Having certain level of chemical inertness to most Active Pharmaceutical Ingredients (APIs) can prevent API degradation even during long term storage;
Safe and well tolerated: HFA 134a propellant has a fast elimination, with no evidence of accumulation in the body;
Ozone-friendly: ODP 0.
HFA 134a Propellant Development History
1.The Montreal Protocol drove the phase out of classic propellants based on refrigerant CFC-11/12/114 with a high ODP;
2.Intermediate stage (1990s) – coming in of the pharmaceutical companies (like GSK) to reformulate pMDIs where HFA 134a propellant and HFA 227ea came into association were two major alternatives available;
3.Industry Maturity: Guidelines on quality and impurity for pharmaceutical-grade HFA 134a propellant (e.g. moisture, residual solvents, chlorides, non-volatile residue) have been established by the European Medicines Agency (EMA) and US FDA to drive standardization efforts;
4.Standardizing the Supply Chain: Defines the new pharmaceutical-grade filling, analytical and purification systems (molecular sieve drying, multi-stage distillation);
5.Additionally, new pressures for ecological and carbon footprint reductions are further driving the industry towards next-generation ultra-low GWP propellants ( e.g.: HFO-1234ze), as well as modifications of previous uses of HFA-152a (e.g., that used previously in Epinephrine): Although not ozone-depleting ((ODP ≈ 0, GWP ≈1300 on 100 year timeframe, per IPCC AR6 Summary [https://www.ipcc.ch/report/ar6/wg1/];
Current trend: a two-pronged strategy – on the one hand, to maintain a stable supply of HFA 134a propellant in inhaled formulations for key chronic diseases (asthma, COPD); on the other hand, to reduce total emissions by optimizing valves, microparticle engineering and low-dose valve consumption.
HFA 134a Propellant Specifications
- Quality and Safety of HFA 134a propellant. As a propellant, HFA 134a has to satisfy very high quality and safety requirements, especially when used in pharmaceuticals;
- Pharmaceutical grade HFA 134a should have a purity of ≥99.99%, with the moisture not more than 10ppm to prevent from altering the stability of the drug or the efficiency of the delivery;
- Furthermore, it has to be ensured that HFA 134a is compatible with the API and the excipients used in the inhaler, so that no degradation or influence on drug release occurs;
- In terms of regulation, when HFA 134a is used in pharmaceuticals, documents such as the Drug Master File (DMF) must be submitted to comply with the requirements of agencies such as the U.S. Food and Drug Administration (FDA);
- In order to ensure safety, HFA 134a must be stored in cool, dry, ventilated place, keep away from fire, heat and sunshine.
The fundamental distinction between HFA 134a and R134a:
While both are 1,1,1,2-tetrafluoroethane based, this distinction between “R134a” serves to separate the differentiation of ‘grade’, with “R134a” referring to refrigeration/auto AC grade, and “HFA 134a propellant” indicating pharma-grade propellants that meet quality and regulatory requirements of pharmaceutical propellants.
| Dimensions | HFA 134a (pharmaceutical grade) | R134a (industrial/refrigerationgrade) |
|---|---|---|
| Purity and Impurities | The total impurities are lower (typically from ≥99.5 to 99.9%), along with very strict limitations on moisture, non-volatile residues and halogenated impurities | Observe moisture, acidity and n.c.g., but relaxed control over the impurity profiles |
| Manufacturing system | Separate pharmaceutical grade GMP/GMP-like production line for the cross-contamination free handling of | Chemical grade commodity system |
| Batch-to-batch uniformity | Should support formulation reproducibility and uniform dose to the lung | Refrigeration and thermodynamics evaluation |
| Regulatory Documents | DMF (Drug Master File), CEP or national pharmacopoeias (where applicable) | Industrial standards (e.g. ASHRAE, EN standards) |
| End user applications | pMDI, skin topical aerosol | Refrigeration cycle, foaming, cleaning and so on |
| Trace residuals | Impurities can impact stability and taste/airway irritation of the API; maybe 20-30% loss from one impurity alone | No systematic evaluation of human inhalation |
HFA 134a Propellant: Advantages and Disadvantages
Advantages
Lowest Risk, High Maturity: Many commercially successful pMDIs for asthma and COPD reducing the development risk;
Stability & Compatibility: Provides physicochemical compatibility proven with ICS, LABA, LAMA—allowing formulation without complex excipients;
Patient Compliance: More user-friendly for patients with low lung capacity, children and elderly (no high inhalation flow rate as per DPI);
Standardization: The standardized valve and tank components make the technology easy to transfer between multiple plants globally;
ODP ≈ 0: Compliant with the ozone protection policies and not subject to CFC strict phase-out requirement.
Limitations
- 1300 GWP (High Value);
- Lifecycle Emissions: Mainly in the use phase (spray release) due to concerns of greehouse gas leaking;
- If the spraying process is too fast, static electricity may accumulate, affecting the patients’ feelings during their first use;
- Work involving Particle Engineering in Suspension/Solution Systems: Dosage uniformity —control of particle size (MMD, MMAD) and optimization for valve shear;
- Supplier power (greater): There are few suppliers of the limited pharmaceutical-grade purification capacity, and prices can be influenced by availability, as well as geopolitical considerations or changes in the upstream raw material hydrofluoric acid chemical industry.
HFA 134a Propellant Applications
Respiratory Metered-Dose Inhaler (pMDI)
- A Contact for help • Short-acting β2-agonist (SABA);
- Maintenance Therapy: ICS, ICS+LABA Combination, LABA+LAMA, Triple Combination PHAIII-IVAL-like (ICS + LABA + LAMA) well-sprayed; HFA 134a Propellant brings desired spray droplet size distribution(MMAD is 1–5 μm typically), penetrates tiny and medium airways with ease.
Skin and Nasal Topical Aerosol
- Anti-inflammatory, Analgesic and Skin Barrier Repair Spray (Inert propellant to reduce irritation from excipients);
- Nasal topicals in microvolume applications, with formulation limits are the following;
Veterinary Inhalation and Topical Preparations
- Adjunctive treatment for pet asthma/bronchitis, suitable for spillover from human formulations.
Process and Formulation Technology Iteration Platform
- Microsuspension and ultrafine particle engineering to improve lung deposition efficiency and reduce dose.
The role of a "bridge propellant" in the transition period
- Supporting treatment continuity before low-GWP solutions are fully commercialized, preventing patient compliance losses due to formulation switching.
Conclusion
HFA 134a propellant, as a mature, stable, and ozone-free propellant platform in the pharmaceutical industry, continues to hold irreplaceable short- and medium-term value in the management of chronic respiratory diseases. The core difference of HFA 134a from R134a lies not in its chemical formula but in its pharmaceutical-grade purification, impurity profile control, regulatory compliance, and clinical predictability.
Overall, HFA 134a propellant will maintain its dual role as a “main force + transition” in the pMDI field in the coming years, and its sustainable development value depends on companies’ early actions in emission reduction technologies and gradient verification of alternative propellants.
Related Products
Recent Posts
Product Type
Contact Us
WhatsApp:
Email:
Phone:
FAQ
Online payment, T/T, L/C, DP, Western Union, Credit Cards, or please contact us for further confirmation
Disposable Cylinder: 15lbs, 30lbs, 50lbs;
CE Cylinder: 12L, 13.6L, 50L;
DOT: 30lbs, 50lbs;
Besides, we can provide 50L, 60L, 100L, 400L, 500L, 800L, 926, 1000L cylinders, and low & high pressure tank.
Please click here for more details about our refrigerant packaging.
1. Due to shipping fee, our MOQ usually are 1150 cylinders (13.6kg), especially for destinations farther away, like South America or Africa;
2. For destinations that are relatively close or customers who are willing to bear the freight, 300-500 cylinders are OK, but please contact us for specific confirmation;
3. For some special refrigerants, like R508B and R23, the minimum order quantity can be less, please contact us for specific confirmation;
4. Please note that due to transportation or freight issues, we generally do not do retail. For one or two cylinders, please buy directly from local distributors. Thank you for your understanding.
Refrigerant prices are affected by international shipping costs, order quantity, or refrigerant industry fluctuations.
Please contact us with your destination port, refrigerant packaging and order quantity, our colleague will contact you soon for the relevant things about the price.
Yes, the import license is necessary. Besides, for EU customers, they also need HFC quota. If you are not sure of this, please contact us for more details.
Our factory is located in Quzhou City, Zhejiang Province, China. Welcome to visit our factory.
According to relevant Indian policies, refrigerant packaging must be ISO Tank.